Mice treated with CUR plus gemcitabine had a significant decrease in tumor volume and significant down-regulation of NF-κB-regulated genes (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, COX-2, matrix metalloproteinase, and VEGF) compared to control- and gemcitabine-treated mice [125]. This evidence concerns the gene BCL2L1 and neoplasm.